{"id":"W4399318772","doi":"10.1200/jco.23.02736","title":"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"North York General Hospital","funders":"Cilag; Genentech; Sirtex Medical; Daiichi Sankyo Europe; Servier; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Chugai Pharmaceutical; Seagen; Daiichi Sankyo Company; BeiGene; Halozyme; Mirati Therapeutics; Taiho Pharmaceutical; Array BioPharma; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Les Laboratories Pierre Fabre; PharmaMar; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Colorectal cancer; Lenvatinib; Oncology; Internal medicine; Open label; Randomized controlled trial; Cancer; Immunotherapy; Thyroid cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007303047,0.001746298,0.003141896,0.0005086865,0.0003960351,0.001604722,0.001328859,0.001657294,0.005505388],"category_scores_gemma":[0.004295117,0.0006443823,0.003971638,0.0006053183,0.001009363,0.001294795,0.0006495199,0.003576973,0.0009551643],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001015847,"about_ca_system_score_gemma":0.0016979,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008440656,"about_ca_topic_score_gemma":0.002011176,"domain_scores_codex":[0.9967242,0.002473099,0.000126938,0.0002513456,0.0001886789,0.0002358578],"domain_scores_gemma":[0.9970161,0.001133327,0.0006310259,0.0002541859,0.0002134624,0.0007519518],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9782571,0.005050829,0.001010314,0.0005044301,0.002760572,0.00003325629,0.00002932434,0.0004554624,0.001213508,0.0001118567,0.00113563,0.009437811],"study_design_scores_gemma":[0.9199259,0.07359324,0.002917595,0.000047112,0.00159962,0.00003074142,0.00002400486,0.0005782444,0.0002898604,0.0001389672,0.0008392734,0.00001543235],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9667645,0.008969159,0.001897808,0.0015421,0.0006756454,0.01025169,0.005466901,0.0001999851,0.004232119],"genre_scores_gemma":[0.9735204,0.003749634,0.00281258,0.001866424,0.0006398765,0.009294225,0.00485052,0.00006058194,0.00320572],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007303047,"threshold_uncertainty_score":0.03862268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1967053973625952,"score_gpt":0.5371934962452657,"score_spread":0.3404880988826705,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}